AstraZeneca starts three-year restructuring with up to $2bn in charges; shares rise
AstraZeneca launched a three-year "reshaping for sustainable growth" programme aimed at $1.5bn of annual savings to reinvest in its drug pipeline, alongside third-quarter results ahead of forecasts. Shares rose about 3% in early trading.
1 / 3
The story, neutrally told
Mixed · 2AstraZeneca on Friday 30 October launched a three-year restructuring programme, called "reshaping for sustainable growth", intended to free up money to invest in its drug pipeline. Evening StandardN “The company has initiated the ‘reshaping for sustainable growth’ programme to create additional capacity to invest behind its industry-leading pipeline and transformative technologies.” Read at Evening Standard ↗ City A.M.RC “launched a $2bn (£1.5bn) restructuring programme to boost investment in its drug channel” Read at City A.M. ↗ Mixed · 2The programme is expected to cost up to $2bn (£1.5bn) in restructuring charges and to deliver savings of $1.5bn (£1.1bn) a year, which the company said would be reinvested, principally in the pipeline. Evening StandardN “the three-year overhaul would cost it up to two billion dollars (£1.5 billion) in restructuring charges”“The savings generated will continue to be reinvested back into the company, principally in the pipeline.” Read at Evening Standard ↗ City A.M.RC “deliver $1.5bn in annual savings which will be allocated to the programme” Read at City A.M. ↗ Mixed · 2The company said the programme will redeploy resources and strengthen capabilities across its existing business and therapy areas. According to the Evening Standard, it declined to say where the savings would come from or whether jobs would be affected. Evening StandardN “declined to provide details on where the savings would come from and whether jobs would be impacted” Read at Evening Standard ↗ City A.M.RC “shift resources across both its business and therapy areas” Read at City A.M. ↗
Centre · 1AstraZeneca employs about 100,000 people worldwide, around 10,000 of them in the UK, with its global headquarters in Cambridge and UK sites in Macclesfield, London and Speke, Liverpool. Evening StandardN “Anglo-Swedish AstraZeneca employs 100,000 workers globally, of which around 10,000 are based in the UK.” Read at Evening Standard ↗ Right · 1Shares rose 3.1% to £134.50 in early trading, as investors welcomed the plans, according to City A.M. City A.M.RC “The pharmaceutical giant’s shares increased 3.1 per cent to £134.50 on Friday morning” Read at City A.M. ↗ Mixed · 2The announcement came with third-quarter results that beat forecasts: revenue rose 7% to $16.2bn, with double-digit growth in oncology, respiratory and immunology, and rare disease, while pre-tax profit rose 22% to $3.96bn and operating profit rose 22% to $4.39bn. City A.M.RC “revenue climbed seven per cent in the third quarter to $16.2bn, bolstered by double-digit growth in its oncology, R&I and rare disease arms” Read at City A.M. ↗ Evening StandardN “pre-tax profits jumping 22% higher to 3.96 billion dollars (£2.9 billion)”“Operating profits also rose 22% to 4.39 billion dollars (£3.21 billion).” Read at Evening Standard ↗
Right · 1City A.M. said growth offset the loss of patent protection on Farxiga and Brilinta, and that AstraZeneca reiterated full-year guidance of mid-to-high single-digit revenue growth. It also reported approval of 47 projects in the first nine months of the year, including four new medicines. City A.M.RC “The performances offset headwinds from big-selling medicines Farxiga and Brilinta losing patent protection”“The company also achieved approval of 47 projects in the first nine months of the year, including for four new medicines.” Read at City A.M. ↗ Centre · 1Chief executive Pascal Soriot said that with multiple potential blockbuster assets in late-stage development, the company is on track to deliver its 2030 ambition of $80bn in annual sales. The Evening Standard reported more than 180 pipeline projects and about 20 expected new medicine launches. Evening StandardN “we are on track to deliver our 2030 ambition and to sustain growth through the next decade”“with more than 180 projects in the pipeline” Read at Evening Standard ↗ Right · 1City A.M. gave context: shares had weakened earlier in the year after trial problems, including with heart disease drug Wainua, and investor concerns over a potential $400bn merger with Bristol Myers Squibb. Three big cancer drugs also lose patent protection early next decade. The shares are up 7.7% over 12 months. City A.M.RC “Shares had weakened earlier in the year following problems with trials, including heart disease drug Wainua, coupled with investor concerns on its potential $400bn blockbuster merger with Bristol Myers Squibb.”“The Cambridge-based business has notched a 7.7 per cent share price gain over the last 12 months.” Read at City A.M. ↗
Right · 1City A.M. also noted recent deals: a $2bn investment in Summit Therapeutics in September for a 12% stake, and an AI drug partnership with Insitro worth up to $1.5bn. City A.M.RC “agreeing to invest $2bn in Nasdaq-listed Summit Therapeutics in September in exchange for a 12 per cent stake”“signed a drug partnership with California-based AI therapeutics company Insitro earlier this month in a deal with up to $1.5bn” Read at City A.M. ↗
Every sentence links to the reporting it rests on. The pill in front of each says where its sources sit: Left, Centre or Right when one side supplies at least half of them, Mixed when they are evenly split. The number is how many outlets it cites.
Left0 outlets
No left outlet in our sources has covered this story yet.
Centre2 outlets
- Framing
- The Evening Standard frames the story as a cost-cutting overhaul, with a UK workforce angle.
- Emphasis
- The £1.1bn annual saving, lack of detail on jobs, UK headcount and sites, and profit figures.
- Leaves out or plays down
- Does not report the share price reaction, the earlier trial setbacks, patent losses or the merger concerns.
- Charged language
- “slash costs”“overhaul”
- For example
-
“has unveiled plans to slash costs by 1.5 billion US dollars (£1.1 billion) a year” — Evening Standard
Right1 outlet
- Framing
- City A.M. leads with the market reaction and investor optimism, presenting the programme as investment in the pipeline.
- Emphasis
- Share price move, recent setbacks, patent losses, the Bristol Myers Squibb merger concern, and deals with Summit and Insitro.
- Leaves out or plays down
- Does not mention the company's refusal to say where savings come from or the job implications, nor the UK workforce.
- Charged language
- “investors cheered”“jumped”
- For example
-
“as investors cheered plans to bolster its drug pipeline” — City A.M.
What every side reports
- AstraZeneca launched a three-year restructuring programme costing up to $2bn and targeting $1.5bn in annual savings.
- The savings are to be reinvested in the drug pipeline.
- Third-quarter results beat expectations.
- Pascal Soriot said the company is on track for its 2030 ambition.
Where accounts differ
-
How to characterise the programme
- Centre
- A cost-cutting overhaul, with no detail given on job impact.
- Right
- A restructuring to boost investment in the drug pipeline, welcomed by investors.
AstraZeneca organisation
Presents the programme as creating capacity to invest in its pipeline, with savings reinvested, and says it is on track for its 2030 ambition.
“The savings generated will continue to be reinvested back into the company, principally in the pipeline.” — Evening Standard
“on track to deliver our 2030 ambition and sustain growth” — City A.M.
Left0 articles
No coverage yet.
Centre2 articles
-
AstraZeneca launches overhaul to cut costs by £1.1bn a year
Neutral Cost-cutting story stressing savings, unanswered questions on jobs, and UK footprint.
-
STATN ·
Right1 article
-
Astrazeneca shares jump as it kicks off $2bn drug pipeline investment
Celebratory Market-focused report portraying the programme and results as welcomed by investors.
- 30 Oct 10:03 First City A.M.RC Astrazeneca shares jump as it kicks off $2bn drug pipeline investment
- 30 Oct 11:36 +1h 33m Evening StandardN AstraZeneca launches overhaul to cut costs by £1.1bn a year
- 30 Oct 13:22 +3h 20m STATN STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more
Times are when each article was published, or when we first saw it if the outlet gave no time.
Ask about this story
Loading…